Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MasterKey-01: BDTX-189 in Advanced Solid Malignancies
NCT04209465Phase 1Terminated
- Sponsor
- Black Diamond Therapeutics
- Start
- Dec 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of tuxobertinib in solid tumor, sponsored by Black Diamond Therapeutics. Primary endpoint: Dose Limiting Toxicities at 21 days. Started Dec 2019; status: terminated.
02
Drugs
tuxobertinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04209465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209465.